{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T10:42:20Z","timestamp":1794998540580,"version":"4.9.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.eururo.2024.07.016","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T03:54:57Z","timestamp":1723694097000},"page":"503-512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study"],"prefix":"10.1016","volume":"86","author":[{"given":"Talal","family":"El Zarif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Semaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zarba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wadih","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajjai","family":"Alva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Beckermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Stellato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anezka","family":"Zemankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohuslav","family":"Melichar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mollica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedyeh","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"de Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard Paul","family":"Gurney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omi","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Winquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj","family":"Master","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham Ruiz","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan Javier","family":"Cutuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Robert","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Gross-Goupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvan C.","family":"Baca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.C.","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.07.016_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2024.07.016_b0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of renal cell carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J Oncol"},{"key":"10.1016\/j.eururo.2024.07.016_b0015","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.07.016_b0020","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.07.016_b0025","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma","volume":"388","author":"Choueiri","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.07.016_b0030","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.07.016_b0035","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.07.016_b0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5101","article-title":"PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143)","volume":"38","author":"Haas","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.07.016_b0045","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.07.016_b0050","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","article-title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial","volume":"401","author":"Motzer","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.07.016_b0055","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4602","article-title":"LITESPARK-022: A phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC)","volume":"40","author":"Choueiri","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.07.016_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106482","article-title":"RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse","volume":"108","author":"Oza","year":"2021","journal-title":"Contemporary Clinical Trials"},{"key":"10.1016\/j.eururo.2024.07.016_b0065","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.07.016_b0070","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.07.016_b0075","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.07.016_b0080","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.07.016_b0085","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.07.016_b0090","unstructured":"Bourlon MT, Valdez P, Choueiri T, Lam E. Using clinical characteristics to guide treatment of recurrent RCC after adjuvant pembrolizumab. https:\/\/dailynews.ascopubs.org\/do\/using-clinical-characteristics-guide-treatment-recurrent-rcc-after-adjuvant."},{"key":"10.1016\/j.eururo.2024.07.016_b0095","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA359","article-title":"Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC)","volume":"42","author":"Choueiri","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.07.016_b0100","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Jarushka","year":"2023","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.eururo.2024.07.016_b0105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.07.016_b0110","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.annonc.2020.04.471","article-title":"Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy","volume":"31","author":"Owen","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.07.016_b0115","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann Oncol"},{"issue":"661","key":"10.1016\/j.eururo.2024.07.016_b0120","first-page":"e7","article-title":"Metastatic renal cell carcinoma: patterns and predictors of metastases\u2014a contemporary population-based series","volume":"35","author":"Chandrasekar","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.016_b0125","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2214\/AJR.07.2077","article-title":"Imaging in metastatic renal cell carcinoma","volume":"189","author":"Griffin","year":"2007","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.eururo.2024.07.016_b0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.eururo.2016.06.019","article-title":"PSMA-targeted 18F-DCFPyL PET\/CT imaging of clear cell renal cell carcinoma: results from a rapid autopsy","volume":"71","author":"Gorin","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.016_b0135","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/RLU.0000000000000995","article-title":"Detection of 18F-FDG PET\/CT occult lesions with 18F-DCFPyL PET\/CT in a patient with metastatic renal cell carcinoma","volume":"41","author":"Rowe","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2024.07.016_b0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2011.41.2445","article-title":"Positron emission tomography\/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial","volume":"31","author":"Divgi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.07.016_b0145","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/annonc\/mdq554","article-title":"Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib","volume":"22","author":"Beuselinck","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.07.016_b0150","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","article-title":"Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy","volume":"65","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.016_b0155","doi-asserted-by":"crossref","first-page":"e2021869","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival","volume":"4","author":"Dudani","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.eururo.2024.07.016_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100634","article-title":"Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program","volume":"7","author":"Rebuzzi","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.eururo.2024.07.016_b0165","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1200\/JCO.2022.40.6_suppl.287","article-title":"Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC)","volume":"40","author":"McKay","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.07.016_b0170","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2024.07.016_b0175","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8970173","article-title":"Immune checkpoint inhibitor therapy for bone metastases: specific microenvironment and current situation","volume":"2021","author":"Liu","year":"2021","journal-title":"J Immunol Res"},{"key":"10.1016\/j.eururo.2024.07.016_b0180","doi-asserted-by":"crossref","first-page":"77.e17","DOI":"10.1016\/j.urolonc.2020.08.011","article-title":"Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era","volume":"39","author":"Ishihara","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.016_b0185","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/S1470-2045(13)70569-2","article-title":"Radiotherapy for renal-cell carcinoma","volume":"15","author":"De Meerleer","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.07.016_b0190","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824024990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824024990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T23:47:31Z","timestamp":1733874451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824024990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0302283824024990"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.07.016","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}